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ABSTRACT 
Congenital melanocytic nevi (CMN) are cutaneous malformations whose prevalence is inversely 
correlated with projected adult size. CMN are caused by somatic mutations, but epidemiological studies 
suggest that germline genetic factors may influence CMN development. In CMN patients from the U.K., 
genetic variants in MC1R, such as p.V92M and loss-of-function variants, have been previously 
associated with larger CMN. We analyzed the association of MC1R variants with CMN characteristics 
in two distinct cohorts of medium-to-giant CMN patients from Spain (N=113) and from France, 
Norway, Canada and the U.S. (N=53), similar at the clinical and phenotypical level except for the 
number of nevi per patient. We found that the p.V92M or loss-of-function MC1R variants either alone 
or in combination did not correlate with CMN size, in contrast to the U.K. CMN patients. An additional 
case-control analysis with 259 unaffected Spanish individuals, showed a higher frequency of MC1R 
compound heterozygous or homozygous variant genotypes in Spanish CMN patients compared to the 
control population (15.9% vs. 9.3%; P=0.075). Altogether, this study suggests that MC1R variants are 
not associated with CMN size in these non-UK cohorts. Additional studies are required to define the 
potential role of MC1R as a risk factor in CMN development. 
 
SIGNIFICANCE  
Congenital melanocytic nevi (CMN) are common pigmented lesions without clear evidence of a genetic 
predisposition. Limited data exist regarding the role of MC1R, key pigmentation gene, in the 
development of rare CMN subtypes, which are >10 cm in adulthood and associated with increased 
morbidity and mortality risks. Data from our large set of such CMN patients suggest that MC1R could 
be involved in the development of these lesions, but at the same time discount its influence on CMN 
size across distinct populations. Improving our understanding of genetic susceptibility to rare CMN is 
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Congenital melanocytic nevi (CMN) are benign melanocytic tumors of the skin, which are present at 
birth or become visibly pigmented during the first years of life (Price & Schaffer, 2010). CMN are 
classified based on the projected adult size (PAS) of the largest lesion (Krengel, Scope, Dusza, Vonthein, 
& Marghoob, 2013). Large (PAS 20-40 cm in diameter) and giant (PAS > 40 cm) CMN are rare lesions 
found in approximately 1/20,000 to 1/50,000-100,000 newborns, respectively (Alikhan, Ibrahimi, & 
Eisen, 2012). This subset of patients has an increased risk of developing pediatric and adult melanoma 
within the lesion, the viscera or the central nervous system (CNS) (Kinsler et al., 2017). Furthermore, 
these patients may present other CNS abnormalities, including neurocutaneous melanosis and brain 
tumors (Foster et al., 2001; Jakchairoongruang, Khakoo, Beckwith, & Barkovich, 2018), Dandy-Walker 
malformations (De Cock, Snauwaert, Van Rompaey, Morren, & Demaerel, 2014; Marnet et al., 2009; 
Schreml et al., 2008; Walbert, Sloan, Cohen, & Koubeissi, 2009), arachnoid cysts (Peters, Jansen, & 
Engelbrecht, 2000), tethered spinal cord (Foster et al., 2001; Tian, Foster, Jakacki, Reyes-Mugica, & 
Greene, 2015), hydrocephalus (Hsueh, Ho, Chiu, & Shen, 2004; Peters et al., 2000) or epilepsy (Wen et 
al., 2001). Large and giant CMN may occur in isolation or as part of a syndrome with variable 
phenotypic expression (Kinsler, Shaw, Merks, & Hennekam, 2012a). CMN lesions are characterized 
according to a consensus classification including the anatomic location, further broken down into 
stereotypical distribution patterns (the “6B” scheme” in giant CMN (Martins da Silva et al., 2017) and 
the “biker glove” pattern in CMN of the extremities (Kittler, Mathes, Kinsler, & Frieden, 2019)); color 
heterogeneity; surface rugosity; presence of hypertrichosis; nodularity; and numbers of “satellite” or 
multiple CMN that appear during the first years of life or are visible at birth (Krengel et al., 2013). In 
this paper, we use the term “multiple CMN” instead of “satellite” and in contrast to “single CMN”, when 
the patient exhibits more than one CMN with different sizes (Kinsler, 2011). 
CMN seem to be caused by the acquisition of a postzygotic somatic mutation that constitutively activates 
the MAPK signaling pathway in a melanocyte-competent cell lineage. These events include oncogenic 
point mutations in the BRAF and NRAS genes, which are the most recurrent alterations (Bauer, Curtin, 
Pinkel, & Bastian, 2007; Charbel et al., 2014; Polubothu et al., 2019), but also chromosomal 
rearrangements (Baltres et al., 2019; Dessars et al., 2007; Martins da Silva et al., 2019). Although CMN 
are the result of somatic mosaicism, epidemiological data and case reports of familial recurrence in up 
to 25% of second-degree relatives, as opposed to approximately 1% of the general population, suggest 
the existence of a germline predisposition for CMN (Danarti, Konig, & Happle, 2003; Kinsler, Birley, 
& Atherton, 2009; de Wijn, Zaal, Hennekam, & van der Horst, 2010).  
A study conducted in CMN patients from the U.K. concluded that the presence of germline variants in 
the melanocortin-1-receptor (MC1R) gene was both a risk factor for CMN development and that the 
presence of certain germline variants may modulate the size of the CMN (Kinsler, Abu-Amero, et al., 
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2012). The MC1R gene, a key regulator of human pigmentation (Dessinioti, Antoniou, Katsambas, & 
Stratigos, 2011; Sturm, 2009), is highly polymorphic in populations of European origin (Gerstenblith, 
Goldstein, Fargnoli, Peris, & Landi, 2007). Many MC1R variants are hypomorphic alleles that cause 
various degrees of loss of the receptor’s ability to activate eumelanin synthesis. Some of these are 
strongly associated with the “red hair color” (RHC) phenotype, characterized by fair skin, red hair, 
freckles, high UV radiation sensitivity and lack of tanning ability (Valverde, Healy, Jackson, Rees & 
Thody, 1995). The most common RHC variants have been classified according to their phenotypic 
penetrance into high-penetrance “R” or lower-penetrance “r” alleles (reviewed in Herraiz, Garcia-
Borron, Jiménez-Cervantes & Olivares, 2017). Both R and r alleles have also been associated with 
increased melanoma risk, (Hu et al., 2014; Palmer et al., 2000; Raimondi et al., 2008; Tagliabue et al., 
2018; Williams, Olsen, Hayward, & Whiteman, 2011) or with a specific melanoma clinicopathological 
subtype (Puig-Butille et al., 2013), particularly in R/R but also R/r combinations. These “red hair” alleles 
also exert similar influence on melanoma risk, hair color and skin phototype in Mediterranean 
populations, such as the Spanish (Fernandez et al., 2007). Indeed, most but not all people with red hair 
do carry two MC1R variants, some of whom express “r” variants in epistasis with other gene loci, yet 
people carrying two variant MC1R alleles are more likely to have light brown or blonde hair than red 
(Morgan et al., 2018). Within the U.K. CMN cohort, MC1R status comprising a p.V92M “r” allele, any 
“R” allele, or both, when taken together was significantly associated with increasing CMN size, most 
so for those patients with G2-sized giant CMN (PAS > 60 cm) (Kinsler, Abu-Amero, et al., 2012). This 
study aims to analyze the impact of MC1R variants on phenotypic attributes of CMN in two multicentric 
cohorts of medium-to-giant CMN patients from different European and North American countries.  
2. MATERIALS AND METHODS 
2.1. Participants  
Each study participant and/or their parent or legal guardian signed written informed consent, as 
appropriate. All aspects of this study comply with the declaration of Helsinki. 
Overall, the study included 166 patients with medium, large or giant CMN from independent fair-
skinned populations. In all cases, CMN lesions were phenotypically classified following the latest 
consensus classification (Krengel et al., 2013) (Table 1), and giant CMN were additionally classified 
following the 6B guidelines (Martins da Silva et al., 2017) (Supporting table S1).  
2.1.1. Spanish CMN Patient Cohort 
The Spanish cohort included 113 patients from Spain recruited at the Hospital Clínic of Barcelona 
(HCB) and through the Spanish association of patients with large or giant CMN (Asociación Española 
de Nevus Gigante Congénito or Asonevus). Clinical and phenotypic data were obtained by direct 
examination and/or digital photographs by trained dermatologists from the HCB patients and by self-
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reported questionnaires from the Asonevus patients. The Asonevus patients were encouraged to answer 
the questionnaire with the guidance of their dermatologist or pediatrician, and to attach photos and 
reports of neonatologists, pediatricians, dermatologists and plastic surgeons they might have consulted, 
in order to assess the accuracy of the phenotypic reporting. Adequate blood or saliva samples for DNA 
extraction were obtained from HCB patients. The Asonevus patients received a saliva collection kit with 
the corresponding instructions for sample collection alongside the questionnaire.  
This study was approved by the Clinical Research Ethics Committee of the HCB.  
2.1.2. Marseille CMN Patient Cohort 
The Marseille cohort included 53 patients from different populations that were recruited through a 
multicentric study based at the Aix-Marseille University: three from Norway, 11 from France, two from 
Canada and 37 from the United States. Only phototypes I to IV were included in this study in accordance 
with the composition of the Spanish cohort. The parents of the French pediatric patients completed 
phenotyping questionnaires with their referring plastic surgeons. Photographs were provided in addition 
to nevus and non-nevus (unaffected skin, blood or saliva) samples. The other CMN patients were 
recruited at the 2010 Nevus Outreach International Conference, completing a similar questionnaire in 
the presence of a pediatric dermatologist and providing blood samples.  
This study was approved by the ethical committee CPP Sud-Méditerranée II (214-C03 from 11 April 
2014) and received the French Ministry of Research authorization (DC2013-1769).  
2.1.3. Spanish control cohort 
In addition to medium-to-giant CMN patients, we included a set of 259 individuals as a control 
population in order to obtain the allelic frequency of MC1R variants in the Spanish population. The 
control individuals were adults (≥18 years old) considered healthy (able to perform normal activities 
and in the case of any chronic condition, this was treated and under control), with none of the following 
criteria: (i) personal history of melanoma, non-cutaneous malignancies, immunosuppression, or 
genodermatosis predisposing to skin cancer (i.e., xeroderma pigmentosum, albinism, or Gorlin 
syndrome), (ii) familial history of melanoma in first-degree relatives, (iii) pregnant women, and (iv) 
relatives of another control individual in the same study.  
2.2. MC1R Genotyping 
Genomic DNA was isolated from peripheral blood lymphocytes or from epithelial cells in saliva 
samples. Genomic DNA from the Spanish cohort blood samples was isolated using the CMG-715 
ChemagicTM DNA blood kit with the automated method ChemagicTM MSM1 (Chemagen, Baesweiler, 
Germany), or using an Autopure LS (Qiagen, Hilden, Germany) workflow from the Marseille cohort 
samples. Saliva was collected in OG-500 or OG-575 Oragene® saliva collection kits, depending on the 
age of the patient, and DNA was extracted using the prepIT®-L2P reagents (DNAGenotek, Ontario, 
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Canada). Polymerase chain reaction (PCR) was used to amplify two overlapping fragments of the MC1R 
coding region using the following primers: NT-F, 5’-
TGTAAAACGACGGCCAGTGCAGCACCATGAACTAAGCA-3’ together with TM-R, 5’-
CAGGAAACAGCTATGACCTTTAAGGCCAAAGCCCTGGT-3’; and CT-R, 5’-
CAGGAAACAGCTATGACCCAGGGTCACACAGGAACCA-3’ together with TM-F, 5’-
TGTAAAACGACGGCCAGTAACCTGCACTCACCCATGTA-3’. The thermal cycling conditions 
were as follows: 1 cycle of denaturation at 95ºC for 5 min, 35 amplification cycles (94ºC for 1 min, 
55ºC for 1 min, and 72ºC for 3 min), and a final extension at 72ºC for 10 min. The entire MC1R coding 
region was sequenced using universal M13 primers by GENEWIZ (Takeley, UK). Sequences were 
analyzed using SeqPilot 4.0.1 software (JSI Medical Systems, Ettenheim, Germany). 
2.3. Statistical Analysis 
MC1R non-synonymous variants were classified as high-penetrance “R” or low-penetrance “r” alleles 
according to previously reported criteria (Kinsler, Abu-Amero, et al., 2012; Raimondi et al., 2008; 
Vallone et al., 2018). MC1R variants classified as “R” were p.D84E, p.R142H, p.R151C, p.I155T, 
p.R160W, p.R163*, and p.D294H. All other non-synonymous variants, including p.V60L, p.V92M, and 
p.R163Q, were classified as “r”. Synonymous variants were considered equivalent to wild-type MC1R 
alleles. Statistical analysis was performed using the IBM® SPSS® Statistics software package version 
20 (IBM Corp., Armonk, N.Y., USA). Pearson’s chi-squared and Student’s t-tests were used to compare 
categorical and continuous variables, respectively. All tests were two-sided and considered statistically 
significant if the p-value was <0.05.  
3. RESULTS 
3.1. Clinical and Phenotypical Characteristics of CMN Patients 
Two cohorts of medium-to-giant CMN patients were ascertained; these were designated as the Spanish 
Cohort (113 CMN patients recruited at Hospital Clínic of Barcelona or through the Spanish association 
of patients with large or giant CMN (Asonevus)) and the Marseille Cohort (53 CMN patients from 
France, Norway, Canada, and the United States recruited through a multicentric study based at the Aix-
Marseille University). Comparison of clinical and phenotypical features between the Spanish and the 
Marseille cohorts showed no statistical differences in terms of patient age, sex, hair color and projected 
adult size (PAS) or anatomic locations of the lesions (Table 1).  
We categorized all lesions according to the latest consensus classification (Krengel et al., 2013) (Table 
1). The subset of giant CMN lesions (N=97), which accounted for 53.1% and 69.8% of the Spanish and 
the Marseille cohorts, respectively, were also classified according to 6B body distribution patterns 
(Martins da Silva et al., 2017) (Supporting table S1). Both cohorts were similar at the clinical and 
phenotypic level except for the number of multiple CMN in the patient (P=0.002) (Table 1). Patients 
with >50 multiple CMN were nearly twice as frequent in the Marseille cohort compared to the Spanish 
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cohort. This difference between cohorts was restricted to the subset of CMN patients classified as giant 
(Supporting table S2).  
3.2. Molecular Screening of MC1R variants 
We detected nine recurrent non-synonymous MC1R variants in CMN patients, including the “R” 
variants p.D84E, p.R142H, p.R151C, p.I155T, p.R160W, p.D294H, and “r” variants p.V60L, p.V92M, 
p.R163Q (Table 2). In addition, six uncommon MC1R non-synonymous variants were detected in seven 
patients (p.R163*, p.A81P, p.S83P, p.R142C, p.V122M, and p.T262S). The Spanish and the Marseille 
cohort showed significant differences in the allelic frequency of the p.V92M variant (P=0.002) and, to 
a lesser extent, the p.D294H variant (P=0.023) (Table 2). Differences in the allelic frequency of p.V92M 
were restricted to the subset of patients with CMN classified as giant (N=97) (Supporting table S3). 
Overall, we found non-synonymous MC1R variants in 63.9% of CMN patients, corresponding to 59.3% 
and 73.6% of the Spanish and the Marseille cohorts, respectively. Although we found no statistically 
significant differences between both cohorts in terms of the prevalence of MC1R genotypes, we 
observed a lower overall fraction of MC1R variant carriers and compound heterozygous or homozygous 
MC1R genotypes among the Spanish patients (Table 3). 
First, we evaluated whether the presence of MC1R variants had an impact on the phenotypic features of 
CMN. We did not observe any significant association between the presence of MC1R variants and PAS 
or anatomic location of the lesion. For instance, giant CMN patients with the same characteristics in 
terms of multiple CMN count and MC1R genotype showed different clinical presentations of the CMN 
(Figure 1). 
Based on the previous findings observed in U.K. CMN patients (Kinsler, Abu-Amero, et al., 2012), we 
specifically evaluated the association of the p.V92M variant or “R” MC1R alleles with PAS of the 
lesions in our CMN patients (Table 4). We did not observe any association between the p.V92M variant 
and PAS of the CMN when all patients were analyzed together. The presence of any “R” MC1R variant 
alone or in combination with the p.V92M variant was also not associated with CMN size differences. 
However, when we analyzed each cohort separately, we found in the Spanish cohort that the allelic 
frequency of the p.V92M variant was lower in CMN patients with higher PAS (P=0.025). The p.V92M 
variant was observed in 12.9% and 18.2% of Spanish medium and large CMN patients, respectively, 
but only in 1.7% of Spanish giant CMN patients.  
Giant CMN patients differed in the number of multiple CMN between cohorts (Supporting table S2). 
Thus, we assessed whether the number of multiple CMN was a confounding factor for the association 
between the p.V92M variant and the size of the lesion observed in Spanish patients (Supporting Table 
S4). We did not find a significant association between the number of multiple CMN and the presence of 
the p.V92M variant in either CMN cohort, indicating that these were unrelated variables.  
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CMN patients were more likely to have two MC1R variants (compound heterozygous or homozygous) 
than the U.K. control population, regardless of the particular MC1R variant (Kinsler, Abu-Amero, et al., 
2012). To explore the potential role of the MC1R gene as a risk factor for CMN development, we 
performed a case-control analysis comparing the Spanish CMN patient cohort with 259 Spanish control 
individuals. Although no statistically significant differences were observed in the prevalence of MC1R 
variants between groups, we found a higher, but not statistically significant, frequency of compound 
heterozygous or homozygous genotypes in CMN patients compared to the control population (15.9% 
vs. 9.3%; P=0.075) (Table 5). In contrast, the allelic frequency of the p.V92M variant (P=0.868) or the 
presence of any “R” allele (P=0.815) was similar between CMN patients and control individuals 
(Supporting table S5). 
4. DISCUSSION 
In the present study, we have constituted and compared two previously unpublished independent cohorts 
of medium-to-giant CMN patients from different populations: one exclusively from Spain (Spanish 
cohort) and another from diverse origins recruited at Aix-Marseille University (Marseille cohort). We 
analyzed all CMN patients together, as these cohorts exhibit similar clinical and phenotypic features, 
except for the number of multiple CMN that may accompany the principal lesion (“satellites”). Giant 
CMN are significantly associated with higher numbers of such multiple CMN and a higher prevalence 
of other clinical signs of CMN syndrome, such as melanoma or neurocutaneous melanosis (Marghoob, 
Dusza, Oliveria, & Halpern, 2004; Martins da Silva et al., 2017; Price et al., 2015). In the present study, 
the fraction of giant CMN patients was greater in the Marseille cohort (69.8%) compared to the Spanish 
cohort (53.1%). However, the difference in the number of multiple CMN was restricted to the subset of 
giant CMN patients, suggesting that molecular differences may exist between these subsets. 
Based on a previously published cohort of CMN patients from the U.K. (Kinsler, Abu-Amero, et al., 
2012), we assessed the role of certain MC1R variants in CMN development. We analyzed nearly twice 
as many CMN patients as compared to the U.K. cohort (N=166 vs. N=84) and with a higher 
representation of giant CMN (58% vs. 49%). In contrast to the earlier findings, in our study the presence 
of the p.V92M variant and/or any “R” alleles, either alone or in combination, was not associated with a 
larger PAS of the CMN. By analyzing the cohorts independently, we found that the presence of the 
p.V92M variant even protected against developing the largest CMN in the Spanish cohort.  
The allelic frequency of MC1R variants, including the p.V92M variant, differs among populations, being 
lower in Mediterranean populations compared with northern European populations (Dessinioti et al., 
2011; Gerstenblith et al., 2007). Likewise, the Spanish CMN patients carried fewer MC1R variants and 
had a lower frequency of the p.V92M variant compared with the Marseille cohort, which had more 
diverse origins. In contrast, the prevalence of MC1R genotypes was similar between the Marseille and 
the U.K. cohorts (Kinsler, Abu-Amero, et al., 2012). In the U.K. cohort, 52% of giant CMN patients 
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carried either an “R” allele or the p.V92M variant, very similar to the Marseille cohort, where 54% of 
giant CMN patients carried these variants but where the effect of MC1R on size was not replicated. A 
major drawback of studying such a rare and heterogeneous condition is that it is likely that subdivision 
into regions too small to be proxies for populations diminishes our capacity to distinguish real from 
spurious associations. Thus, the significant association of the p.V92M variant with a lower PAS of the 
CMN in Spanish patients might be a spurious result caused by both the low frequency of the variant and 
the limited size of the giant CMN patient subset. Children from dark-skinned populations of sub-Saharan 
Africa, in whom non-synonymous MC1R variants are rare (reviewed in Herraiz et al., 2017), also 
develop the largest, G2-type CMN (Endomba, Mbega, Tochie & Petnga, 2018; Katibi, Ogunbiyi, Brown 
& Adeyemi, 2014). Altogether, these data indicate that MC1R genotype is not likely to contribute to a 
larger CMN size.  
In the U.K. study, the risk for CMN development was associated with the number of MC1R variants 
rather than with the presence of a particular variant (Kinsler, Abu-Amero, et al., 2012). Similarly, in our 
Spanish cohort, we have detected a difference in the prevalence of compound heterozygous or 
homozygous genotypes between patients and controls. The lower proportion of MC1R variant carriers 
in the Spanish population probably affects these results. In the future, further case-control studies should 
be conducted in larger populations with a high prevalence of MC1R variants to resolve whether the 
MC1R genotype has an impact on any relevant aspect of CMN development. 
In conclusion, our study suggests that the MC1R genotype is not associated with the size of CMN. 
However, we cannot rule out the role of MC1R as a risk factor for CMN development, especially in 
carriers of MC1R variants on both alleles. Additional studies in other populations, including detailed 
clinical descriptions following the consensus classifications of all lesions and of the individuals who 
carry them, are necessary to clearly elucidate the role of the MC1R gene in CMN development. 
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Table 1. Clinical features and evaluation of the CMN phenotypic characteristics of the Spanish 
and Marseille CMN patient cohorts 









Marseille) (N=166) (N=113) (N=53)  
Age in years (mean ± SD)  16.81 ± 16.54 17.13 ± 16.65 16.14 ± 16.44 0.720 
Sex 
Male 38.0% (62) 41.6% (47) 30.0% (15) 
0.160 Female 62.0% (101) 58.4% (66) 70.0% (35) 
Missing 3 0 3 
Hair Color 
Red 2.2% (3) 1.0% (1) 6.3% (2) 
0.154 
Blond 20.0% (27) 17.5% (18) 28.1% (9) 
Brown 67.4% (91) 70.9% (73) 56.3% (18) 
Black 10.4% (14) 10.7% (11) 9.4% (3) 
Missing 31 10 21 









Marseille) (N=166) (N=113) (N=53)  
Size (PAS) 
Medium 24.7% (41) 27.4% (31) 18.9% (10) 
0.121 Large 16.9% (28) 19.5% (22) 11.3% (6) 
Giant 58.4% (97) 53.1% (60) 69.8% (37) 
Anatomic 
location 
Only head 21.2% (35) 23.9% (27) 15.4% (8) 
0.462 
Including trunk 66.1% (109) 63.7% (72) 71.2% (37) 
Only extremities  12.7% (21) 12.4% (14) 13.5% (7) 
Missing 1 0 1 
Color 
heterogeneity 
None 35.3% (54)  30.9% (34) 46.5% (20) 
0.141  
Moderate 43.1% (66)  44.5% (49)  39.5% (17) 
Marked 21.6% (33)  24.5% (27)  14.0% (6) 
Missing  13 3 10 
Multiple CMN 
count 
0 28.0% (46) 35.1% (39) 13.2% (7) 
0.002  
<20 26.8% (44)  28.8% (32)  22.6% (12) 
20-50 12.8% (21)  12.6% (14)  13.2% (7) 
>50 32.3% (53)  23.4% (26)  50.9% (27) 
Missing  2 2 0 
Surface 
rugosity 
None 49.7% (76)  44.6% (50) 63.4% (26) 
0.062  
Moderate 41.2% (63)  43.8% (49)  34.1% (14) 
Marked 9.2% (14)  11.6% (13)  2.4% (1) 
Missing 13 1 12 
Nodules 
None 70.9% (107)  74.1% (83)  61.5% (24) 
0.282  
Scattered 17.9% (27)  15.2% (17)  25.6% (10) 
Extensive 11.3% (17)  10.7% (12)  12.8% (5) 
Missing 15 1 14 
Hypertrichosis 
None 21.0% (30) 17.9% (20) 32.3% (10) 
 0.116 
Notable 50.3% (72)  54.5% (61)  35.5% (11) 
Marked 28.7% (41)  27.7% (31)  32.3% (10) 
Missing 23 1 22 
Abbreviation: CMN, congenital melanocytic nevi.
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Table 2. Allelic frequency of the most common non-synonymous MC1R variants in CMN patient 
cohorts  















Marseille) (N=166) (N=113) (N=53) 
p.V60L†  G/T T 0.17 0.18 0.13 0.260 
p.V92M†  G/A A 0.07 0.04 0.13 0.002 
p.R163Q†  G/A A 0.04 0.03 0.06 0.717 
p.D84E‡  C/A A 0.02 0.01 0.03 0.175 
p.R142H‡ G/A A 0.02 0.02 0.00 0.123 
p.R151C‡ C/T T 0.04 0.03 0.06 0.262 
p.I155T‡   T/C C 0.02 0.02 0.02 0.941 
p.R160W‡ C/T T 0.02 0.02 0.02 0.941 
p.D294H‡ G/C C 0.02 0.01 0.05 0.023 
† Low-penetrance RHC variants (“r” variants)    
‡ High-penetrance RHC variants (“R” variants)    

















Wild-type 36.1% (60) 40.7% (46) 26.4% (14) 0.074 
Heterozygous 44.0% (73) 43.3% (49) 45.3% (24) 0.816 
Compound heterozygous  14.5% (24) 11.5% (13) 20.8% (11) 0.114 
Homozygous 5.4% (9) 4.4% (5) 7.5% (4) 0.469 
Compound heterozygous or 
homozygous 
19.9% (33) 15.9% (18) 28.3% (15) 0.063 
Abbreviation: CMN, congenital melanocytic nevi. 
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MC1R genotype  
Presence of p.V92M variant Presence of “R” variant Presence of p.V92M or “R” variant 




Medium  82.9% (34) 17.1% (7) 
0.175 
82.9% (34) 17.1% (7) 
0.183 
65.9% (27) 34.1% (14) 
0.976 Large  78.6% (22) 21.4% (6) 82.1% (23) 17.9% (5) 64.3% (18) 35.7% (10) 




Medium  87.1% (27)  12.9% (4)  
0.025 
87.1% (27)  12.9% (4)  
0.382 
74.2% (23)  25.8% (8)  
0.820 Large  81.8% (18)  18.2% (4)  81.8% (18)  18.2% (4)  68.2% (15)  31.8% (7)  




Medium  70.0% (7)  30.0% (3)  
0.748 
70.0% (7)  30.0% (3)  
0.572 
40.0% (4)  60.0% (6)  
0.917 Large  66.7% (4)  33.3% (2)  83.3% (5)  16.7% (1)  50.0% (3)  50.0% (3)  
Giant  78.4% (29)  21.6% (8)  62.2% (23)  37.8% (14)  45.9% (17)  54.1% (20)  
Abbreviation: CMN, congenital melanocytic nevi; PAS, projected adult size. 
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Table 5. Comparison of the prevalence of heterozygous or homozygous non-synonymous MC1R 
variants between Spanish controls and Spanish CMN patients  
MC1R genotype 
Spanish controls Spanish cohort  
P-value  
(N=259) (N = 113) 
Wild-type 42.5% (110) 40.7% (46) 0.751 
Heterozygous 48.3% (125) 43.3% (49) 0.384 
Compound heterozygous  6.2% (16) 11.5% (13) 0.074 
Homozygous 3.1% (8) 4.4% (5) 0.545 
Compound heterozygous or 
homozygous 
9.3% (24) 15.9% (18) 0.075 




Figure 1. Correlation of MC1R genotype and phenotypic features of patients with giant congenital 
melanocytic nevi (CMN). Examples of whole-body photography of female patients with CMN 
classified as G2 with >50 multiple CMN with either (ai-iii) bathing trunk distribution or (bi-iii) bolero 
distribution, with different MC1R genotypes and different CMN presentations. (i) Wild-type MC1R, (ii) 
presence of one MC1R variant (p.V60L), and (iii) presence of two MC1R variants ((a) p.R151C, 
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Supporting table S1. Patterns of distribution of giant CMN according to the 6B rule  









Marseille) 6B distribution (N=97) (N=60) (N=37) 
Bolero 17.6% (29) 28.3% (17) 32.4% (12) 
0.479 
Back 10.3% (17) 15.0% (9) 21.6% (8) 
Bathing trunk 23.0% (38) 41.7% (25) 35.1% (13) 
Breast/belly 1.2% (2) 3.3% (2) 0.0% (0) 
Body extremity 4.8% (8) 6.7% (4) 10.8% (4) 
Body 1.2% (2) 5.0% (2) 0.0% (0) 
Missing 1 1 0 





Supporting table S2. Evaluation of CMN phenotypic characteristics of the Spanish and Marseille 
CMN patient cohorts, including only (A) medium and large CMN or (B) giant CMN  
A 












(N=69) (N=53) (N=16)  
Color 
heterogeneity 
None 40.0% (26) 34.6% (18) 61.5% (8) 
0.151 
Moderate 46.2% (30) 51.9% (27) 23.1% (3) 
Marked 13.8% (9) 13.5% (7) 15.4% (2) 
Missing  4 1 3 
Multiple CMN 
count 
0 58.2% (39) 62.7% (32) 43.75% (7) 
0.465 
<20 28.4% (19) 23.5% (12) 43.75% (7) 
20-50 7.5% (5) 7.8% (4) 6.25% (1) 
>50 6.0% (4) 5.9% (3) 6.25% (1) 
Missing  2 2 0 
Surface rugosity 
None 62.1% (41) 56.6% (30) 84.6% (11) 
0.155 
Moderate 30.3% (20) 34.0% (18) 15.4% (2) 
Marked 7.6% (5) 9.4% (5) 0.0% (0) 
Missing 3 0 3 
Nodules 
None 87.9% (58) 86.8% (46) 92.3% (12) 
0.580 
Scattered 6.1% (4) 7.5% (4) 0.0% (0) 
Extensive 6.1% (4) 5.7% (3) 7.7% (1) 
Missing 3 0 3 
Hypertrichosis 
None 19.0% (12) 15.1% (8) 40.0% (4) 
0.094 
Notable 58.7% (37) 64.2% (34) 30.0% (3) 
Marked 22.2% (14) 20.8% (11) 30.0% (3) 
Missing 6 0 6       
B   









Marseille) (N=97) (N=60) (N=37)  
Color 
heterogeneity 
None 31.8% (28) 27.6% (16) 40.0% (12) 
0.102 
Moderate 40.9% (36) 37.9% (22) 46.7% (14) 
Marked 27.3% (24) 34.5% (20) 13.3% (4) 
Missing  9 2 7 
Multiple CMN 
count 
0 7.2% (7) 11.7% (7) 0.0% (0) 
0.006 
<20 25.8% (25) 33.3% (20) 13.5% (5) 
20-50 16.5% (16) 16.7% (10) 16.2% (6) 
>50 50.5% (49) 38.3% (23) 70.3% (26) 
Surface rugosity 
None 40.2% (35) 33.9% (20) 53.6% (15) 
0.134 
Moderate 49.4% (43) 52.5% (31) 42.9% (12) 
Marked 10.3% (9) 13.6% (8) 3.6% (1) 
Missing 10 1 9 
Nodules 
None 57.6% (49) 62.7% (37) 46.2% (12) 
0.265 
Scattered 27.1% (23) 22.0% (13) 38.5% (10) 
Extensive 15.3% (13) 15.3% (9) 15.4% (4) 
Missing 12 1 11 
Hypertrichosis 
None 22.5% (18) 20.3% (12) 28.6% (6) 
0.713 
Notable 43.8% (35) 45.8% (27) 38.1% (8) 
Marked 33.8% (27) 33.9% (20) 33.3% (7) 
Missing 17 1 16 
Abbreviation: CMN, congenital melanocytic nevi. 
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Supporting table S3. Allelic frequency of the most common non-synonymous MC1R variants in 
the Spanish and Marseille CMN patient cohorts, including only (A) medium and large CMN or 
(B) giant CMN 
A       



















(N=69)  (N=53) (N=16) 
p.V60L†  G/T T 0.15 0.19 0.03 0.030 
p.V92M†  G/A A 0.09 0.08 0.16 0.170 
p.R163Q†  G/A A 0.04 0.04 0.06 0.547 
p.D84E‡  C/A A 0.01 0.01 0.00 0.581 
p.R142H‡ G/A A 0.01 0.02 0.00 0.434 
p.R151C‡ C/T T 0.04 0.03 0.06 0.364 
p.I155T‡   T/C C 0.00 0.00 0.00 - 
p.R160W‡ C/T T 0.01 0.02 0.00 0.434 
p.D294H‡ G/C C 0.01 0.00 0.03 0.068 
 
      
B       
















(N=97)  (N=60) (N=37) 
p.V60L†  G/T T 0.18 0.18 0.18 0.990 
p.V92M†  G/A A 0.05 0.01 0.12 0.001 
p.R163Q†  G/A A 0.03 0.02 0.05 0.144 
p.D84E‡  C/A A 0.02 0.01 0.04 0.299 
p.R142H‡ G/A A 0.02 0.03 0.00 0.170 
p.R151C‡ C/T T 0.04 0.03 0.05 0.481 
p.I155T‡   T/C C 0.03 0.03 0.03 0.805 
p.R160W‡ C/T T 0.02 0.02 0.03 0.622 
p.D294H‡ G/C C 0.03 0.02 0.04 0.612 
† Low-penetrance RHC variants (“r” variants)    
‡ High-penetrance RHC variants (“R” variants)    
Abbreviation: CMN, congenital melanocytic nevi; RHC, red hair color.  
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MC1R genotype  
Presence of p.V92M variant Presence of “R” variant Presence of p.V92M or “R” variant 




0 82.6% (38) 17.4% (8) 
0.428 
82.6% (38) 17.4% (8) 
0.509 
65.2% (30) 34.8% (16) 
0.995 
<20 86.4% (38) 13.6% (6) 72.7% (32) 27.3% (12) 63.6% (28) 36.4% (16) 
20-50 81.0% (17) 19.0% (4)  76.2% (16) 23.8% (5) 61.9% (13)  38.1% (8) 




0 84.6% (33) 15.4% (6) 
0.156 
82.1% (32) 17.9% (7) 
0.960 
66.7% (26) 33.3% (13) 
0.734 
<20 93.8% (30) 6.3% (2) 78.1% (25) 21.9% (7) 75.0% (24) 25.0% (8) 
20-50 92.9% (13) 7.1% (1) 78.6% (11) 21.4% (3) 78.6% (11) 21.4% (3) 




0 71.4% (5) 28.6% (2) 
0.360 
85.7% (6) 14.3% (1) 
0.630 
57.1% (4) 42.9% (3) 
0.503 
<20 66.7% (8) 33.3% (4) 58.3% (7) 41.7% (5) 33.3% (4) 66.7% (8) 
20-50 57.1% (4) 42.9% (3) 71.4% (5) 28.6% (2) 28.6% (2) 71.4% (5) 
>50 85.2% (23) 14.8% (4) 63.0% (17) 37.0% (10) 51.9% (14) 48.1% (13) 




Supporting table S5. Allelic frequency of the most common non-synonymous MC1R variants 
in the Spanish controls and Spanish CMN patient cohorts 








Spanish CMN  
P-value 
(N=259)  (N=113)  
p.V60L†  G/T  T  0.15 0.18 0.232 
p.V92M†  G/A  A  0.04 0.04 0.868 
p.R163Q†  G/A  A  0.03 0.03 0.970 
p.D84E‡  C/A  A  0.00 0.01 0.032 
p.R142H‡ G/A  A  0.02 0.02 0.522 
p.R151C‡ C/T  T  0.03 0.03 0.765 
p.I155T‡   T/C  C  0.02 0.02 0.822 
p.R160W‡ C/T  T  0.03 0.02 0.446 
p.D294H‡ G/C  C  0.02 0.01 0.473 
† Low-penetrance RHC variants (“r” variants)    
‡ High-penetrance RHC variants (“R” variants)    
Abbreviation: CMN, congenital melanocytic nevi; RHC, red hair color.  
 
 
 
